| AOP | Adverse outcome pathway |
| BPA | Bisphenol A |
| DDT | Dichlorodiphenyltrichloroethane |
| DEHP | Bis(2-ethylhexyl) phthalate |
| DES | Diethylstilbestrol |
| DHEA(S) | Dehydroepiandrosterone(-sulfate) |
| EATS | Estrogen-androgen-thyroid-steroidogenesis |
| EDC | Endocrine disrupting chemical |
| FREIA | “Female Reproductive toxicity of EDCs: a human evidence-based screening and Identification Approach” |
| FSH | Follicle stimulating hormone |
| GnRH | Gonadotropin-releasing hormone |
| GPER | G-coupled protein oestrogen receptor |
| HP(A)G axis | Hypothalamic-pituitary-(adrenal)-gonadal axis |
| IATA | Integrated approach to testing and assessment |
| LH | Luteinizing hormone |
| OECD | Organisation for Economic Cooperation and Development |
| PCOS | Polycystic ovary syndrome |
| POF | Premature ovarian failure |
| POI | Primary ovarian insufficiency |
| REACH | Registration, Evaluation, Authorisation and restriction of CHemicals |
| TG | Test guideline |